Affinity Asset Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Affinity Asset Advisors’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-74,639	Closed	-$1.94M	–	96
2023 Q2	$1.94M	Hold	74,639	–	–	0.68%	38
2023 Q1	$1.55M	Hold	74,639	–	–	0.51%	47
2022 Q4	$1.52M	Hold	74,639	–	–	0.6%	44
2022 Q3	$2.06M	Buy	74,639 +5,934	+9%	+$171K	0.58%	40
2022 Q2	$1.81M	Hold	68,705	–	–	0.76%	33
2022 Q1	$5.5M	Buy	68,705 +11,937	+21%	+$1.47M	0.88%	21
2021 Q4	$11.6M	Buy	56,768 +6,518	+13%	+$1.63M	4.2%	4
2021 Q3	$16.3M	Buy	50,250 +8,334	+20%	+$2.43M	4.1%	4
2021 Q2	$10.9M	Buy	41,916 +14,765	+54%	+$4.5M	3.9%	6
2021 Q1	$10.5M	Buy	27,151 +7,001	+35%	+$2.82M	3.56%	7
2020 Q4	$8.43M	Buy	+20,150	New	+$6.35M	4.47%	6

Other funds holding VINC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Affinity Asset Advisors's VINC Position: Q3 2023 in Review

Affinity Asset Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q3 2023, closing a stake of 74,639 shares — an estimated $1.94M sold.

Affinity Asset Advisors first reported a position in VINC in Q4 2020 and held it in 11 quarters. The position peaked at $16.3M in Q3 2021. 34 funds tracked by Wall St. Rank hold VINC as of Q3 2023.

Affinity Asset Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Affinity Asset Advisors sold 74,639 Vincerx Pharma, Inc. Common Stock shares in Q3 2023, an estimated $1.94M.
Affinity Asset Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Affinity Asset Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $16.3M in Q3 2021.
34 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2023.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.